Amgen INC Form 4 insider transactions

Nancy A. Grygiel, SVP & CCO of Amgen, reports acquiring 1,503 shares of common stock and holding 8,713 shares directly, along with indirect ownership through the 401(k) plan.

Peter H. Griffith, EVP & CFO of Amgen Inc., reports acquiring 7,277 shares of common stock on March 3, 2025.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports acquiring 6,306 shares of common stock on March 3, 2025.

EVP of Global Commercial Operations at Amgen, Murdo Gordon, reports acquiring 8,085 shares of common stock on March 3, 2025.

Matthew C. Busch, VP of Finance & CAO at Amgen, acquired 497 shares of common stock through a dividend reinvestment plan.

Amgen's CEO, Robert Bradway, reported the acquisition of common stock and dividend equivalents, along with holdings in grantor retained annuity trusts (GRATs).

Esteban Santos, EVP of Operations at Amgen, exercised stock options and sold shares on February 19, 2025.

David M. Reese, EVP & Chief Technology Officer of Amgen, reports the exercise of stock options and subsequent sale of Amgen shares.

Amgen's SVP of Human Resources, Derek Miller, reports the sale and acquisition of company stock, including the exercise of stock options.

EVP Murdo Gordon reports the sale of 8,771 Amgen shares at an average price of $294.7947 on February 11, 2025.

Executive Vice President and General Counsel & Secretary of Amgen, Jonathan P. Graham, exercised stock options and sold shares of common stock on February 7, 2025.

Nancy A. Grygiel, SVP & CCO of Amgen, reports the sale of 1,589 shares of common stock at a price of $304.4731 per share on February 5, 2025.

Amgen's Executive Vice President and General Counsel, Jonathan P. Graham, reported gifting 6,430 shares of common stock to irrevocable trusts for his adult children.

Amgen's CEO, Robert Bradway, engaged in transactions involving the transfer of 276,000 common stock shares through gifts and grantor retained annuity trusts.

Rachna Khosla, SVP of Business Development at Amgen, reports the disposition of 212 shares of common stock to cover tax obligations related to vesting restricted stock units.

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports a transaction involving common stock due to tax withholding upon vesting of Restricted Stock Units.

Director Omar Ishrak reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) under the company's incentive program.

Director Charles M. Holley reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Director Michael V. Drake reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Director Omar Ishrak reports the acquisition of Amgen common stock through vested Restricted Stock Units (RSUs) under the company's incentive program.

Director Charles M. Holley reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Director Michael V. Drake reports acquiring Amgen common stock through vested Restricted Stock Units and dividend equivalents.

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports changes in beneficial ownership of Amgen stock due to the disposition of shares to cover tax obligations and acquisitions through the company's 401(k) plan.

Director Amy E. Miles reports acquiring 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs) under the company's director incentive program.

Director Ellen Kullman reports acquiring 719 shares of Amgen common stock on May 31, 2024, through the vesting of restricted stock units.

Director Mary E. Klotman reports acquiring 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs).

Director Tyler Jacks reports the acquisition of 719 shares of Amgen common stock on May 31, 2024, through the vesting of restricted stock units.

Director Omar Ishrak reports acquiring 719 shares of Amgen common stock on May 31, 2024, through the vesting of Restricted Stock Units.

Director Charles M. Holley reports acquiring 719 shares of Amgen common stock and holding 9,574.0209 shares following the transaction on May 31, 2024.

Director Greg C. Garland reports acquiring 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs).